Penumbra, Inc. Announces Presentation of Results of the COMPASS Trial
January 25, 2018 at 07:03 pm
Share
Penumbra, Inc. announced the presentation of the results of the COMPASS Trial, an independent, prospective, multi-center randomized trial that showed the use of Penumbra’s aspiration system was non-inferior to stent retrievers for patients with acute ischemic stroke. The COMPASS Trial results were featured in the main event plenary session at the International Stroke Conference and add to the growing body of evidence demonstrating Penumbra’s aspiration system is an effective frontline thrombectomy approach for acute ischemic stroke as part of the ADAPT (ADirect Aspiration, First Pass Technique) approach. The data showed that the ADAPT technique was non-inferior to stent retrievers for treatment of large vessel occlusions: 52% of patients treated with Penumbra’s aspiration system achieved the primary endpoint of modified Rankin Score (mRS) 0-2 at 90 days compared with 49% of patients treated with stent retrievers. Final revascularization rates were also similar for the two study arms: 92% of patients treated with ADAPT using Penumbra’s aspiration system achieved mTICI 2b-3 revascularization compared to 89% with stent retrievers (p=0.54). Moreover, the percentage of patients achieving TICI 3 was 38% for the ADAPT arm and 29% in the stent retriever arm (p=0.15). The trial also revealed a non-significant trend in revascularization speed that favored aspiration with a 10-minute numeric advantage in achieving reperfusion success (p=0.0194). Secondary safety endpoints presented, including embolization in new territory (ENT) and symptomatic intracranial hemorrhage (sICH), were not statistically different between the two arms. The COMPASS Trial reaffirmed the results of two previous multi-center randomized controlled trials – Penumbra’s 3D Trial and the independent ASTER (Adapt versus StEnt Retriever) Trial – demonstrating improvements in procedure and technique while maintaining a strong safety profile and 90-day clinical outcomes for Penumbra’s aspiration system. COMPASS is the first of the three randomized trials to study the company’s latest reperfusion catheter, ACE™68 with the Penumbra System®.
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
PENUMBRA, INC. 
